{
    "nct_id": "NCT05043090",
    "official_title": "A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)",
    "inclusion_criteria": "* Histologically confirmed unresectable and locally advanced or metastatic PRCC\n* PRCC must be centrally confirmed as MET-driven using a sponsor-designated central laboratory validated NGS assay\n* No prior systemic anti-cancer treatment in the metastatic setting; no prior exposure to MET inhibitors, Durvalumab or Sunitinib in any setting\n* Karnofsky Score >70\n* At least one lesion, not previously irradiated, that can be accurately measured at baseline\n* Adequate organ and bone marrow function\n* Life expectancy â‰¥12weeks at Day 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 130 Years",
    "exclusion_criteria": "* History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement, with or without normal LFTs\n* Spinal cord compression or brain metastases, unless asymptomatic and stable on treatment for at least 14 days prior to study intervention\n* Active or prior cardiac disease (within past 6 months) or clinically significant ECG abnormalities and/or factors/medications that may affect QT and/or QTc intervals\n* Active infection including HIV, TB, HBV and HCV\n* Active or prior documented autoimmune or inflammatory disorders\n* Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention",
    "miscellaneous_criteria": ""
}